The data was published in the 2019 in J Exp Clin Cancer Res. PMID: 30961670
The data was published in the 2019 in J Exp Clin Cancer Res. PMID: 30961670
JAK1 (phospho Tyr1022/1023) antibody
GTX25493
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
ReactivityHuman, Mouse, Primate, Rabbit, Rat
TargetJAK1
Overview
- SupplierGeneTex
- Product NameJAK1 (phospho Tyr1022/1023) antibody - Orthogonal Validated
- Delivery Days Customer9
- Application Supplier NoteICC/IF: 1:250. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID3716
- Target nameJAK1
- Target descriptionJanus kinase 1
- Target synonymsAIIDE; JAK1A; JAK1B; JTK3; tyrosine-protein kinase JAK1
- HostRabbit
- IsotypeIgG
- Protein IDP23458
- Protein NameTyrosine-protein kinase JAK1
- Scientific DescriptionThis gene encodes a membrane protein that is a member of a class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The encoded kinase phosphorylates STAT proteins (signal transducers and activators of transcription) and plays a key role in interferon-alpha/beta and interferon-gamma signal transduction. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]
- ReactivityHuman, Mouse, Primate, Rabbit, Rat
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.Read more
- Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. Shen M et al., 2019 Apr 8, J Exp Clin Cancer ResRead more